Report from the Canadian Melanoma Conference
To view the complete article click
here (pdf format)
At the Canadian Melanoma Conference, Dr. Ribas provided an in-depth look at resistance to cancer immunotherapy in melanoma and presented strategies under development to counter resistance and produce lasting response.
Response to PD-1 blockade therapy requires that the immune system recognize the cancer, and that the cancer allow itself to be recognized. The tumour has to permit the infiltration of T cells, and the T cells need to reach the tumour. If all of this works, patients respond to anti-PD-1 antibody therapy. However, this combination of factors is difficult to achieve.